Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Essentials for Clinicians: Breast Cancer - Editors and Contributors

Editors

  • Fatima Cardoso, Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
  • Vesa Kataja, Central Finland Health Care District, Jyväskylä Central Hospital, Jyväskylä, Finland
  • Vivianne Tjan-Heijnen, Maastricht University Medical Centre, Maastricht, Netherlands

Series editor: Michele Ghielmini, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland

Contributors

Chapter 1 - Diagnosis and Staging of Breast Cancer and Multidisciplinary Team Working

  • H Joensuu - Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland
  • M Leidenius - Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland

Chapter 2 - Pathology (Including Normal Breast) and Disease Subtypes

  • G Viale - Department of Pathology and Laboratory Medicine, European Institute of Oncology, Milan; University of Milan School of Medicine, Milan, Italy
  • MG Mastropasqua - Department of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy

Chapter 3 - Management of Carcinoma In Situ

  • M-J Cardoso - Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
  • C Vrieling - Department of Radiation Oncology, Clinique des Grangettes, Geneva, Switzerland

Chapter 4 - Breast Cancer Surgery

  • P Dubsky - Department of Surgery, Medical University of Vienna, Vienna, Austria; Breast Centre, St. Anna, Lucerne, Switzerland
  • W Haslik - Division of Plastic and Reconstructive Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria

Chapter 5 - Breast Cancer Radiotherapy

  • I Kunkler - Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK
  • V Kataja - Central Finland Health Care District, Jyväskylä Central Hospital, Jyväskylä, Finland

Chapter 6 - Adjuvant Systemic Therapies for Breast Cancer (Including Follow-up)

  • N Turner -‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
  • CD Hart - ‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
  • L Biganzoli - ‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
  • R Blum - ‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
  • M Pestrin - ‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
  • A Di Leo - ‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy

Chapter 7 - Neoadjuvant Chemotherapy and Management of Locally Advanced Disease

  • C Fontanella - German Breast Group, Neu-Isenburg, Germany; Department of Oncology, University Hospital of Udine, Udine, Italy
  • G von Minckwitz - German Breast Group, Neu-Isenburg; University Women’s Hospital, Frankfurt; Senologic Oncology, Düsseldorf, Germany

Chapter 8 - Management of Metastatic Disease (Including Response Assessment)

  • E Senkus - Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
  • A Łacko - Department of Clinical Oncology, Wroclaw Medical University, Wrocław, Poland

 Chapter 9 - Epidemiology of Breast Cancer

  • M Pollán - Cancer and Environmental Epidemiology Unit, National Center of Epidemiology (Pab. 12), Instituto de Salud Carlos III, Madrid, Spain

Chapter 10 - Screening for Breast Cancer

  • V Kataja - Central Finland Health Care District, Jyväskylä Central Hospital, Jyväskylä, Finland

Chapter 11 - Genetic Counselling and Testing

  • O Pagani - Genetic Counselling Service of the Institute of Oncology of Southern Switzerland, Lugano, Switzerland

Chapter 12 - Prognostic and Predictive Factors

  • F Penault-Llorca - Centre Régional de Lutte Contre le Cancer d’Auvergne, Clermont-Ferrand, France

Chapter 13 - New Targets and New Drugs for Breast Cancer

  • G Curigliano - Division of Experimental Cancer Medicine, Istituto Europeo di Oncologia, Milan, Italy

Chapter 14 - Organ-specific Problems in Metastatic Breast Cancer

  • T Cufer - University Clinic Golnik, Golnik, Slovenia

Chapter 15 - Metastatic Breast Cancer in Men

  • F Cardoso - Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
  • B Sousa - Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal

Chapter 16 - Breast Cancer at the Extremes of Age

Part A: Breast Cancer in Young Women

  • S Paluch-Shimon - Breast Oncology Unit, Division of Oncology, Shaare Zedek Medical Centre, Jerusalem, Israel

Part B: Breast Cancer in the Elderly

  • H Wildiers - University Hospitals Leuven, Department of General Medical Oncology, Leuven, Belgium

Chapter 17 - Locally Recurrent Disease

  • H Crezee - Department of Radiation Oncology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
  • O Kaidar-Person - Department of Oncology, Radiation Oncology Unit, Rambam Health Care Campus, Haifa, Israel
  • P Poortmans - Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands; Institut Curie, Paris, France

Declarations of interest

  • L Biganzoli: No conflicts of interest.
  • R Blum: No conflicts of interest.
  • F Cardoso: No conflicts of interest.
  • M-J Cardoso: No conflicts of interest.
  • H Crezee: No conflicts of interest.
  • T Cufer: No conflicts of interest.
  • G Curigliano: Expert testimony for Pfizer, Novartis, Roche Genentech; Member of the Steering committee for randomised clinical trials of Cascadian, Roche Genentech, MacroGenics.
  • A Di Leo: No conflicts of interest.
  • P Dubsky: No conflicts of interest.
  • C Fontanella: No conflicts of interest.
  • CD Hart: No conflicts of interest.
  • W Haslik: No conflicts of interest.
  • H Joensuu: No conflicts of interest.
  • O Kaidar-Person: No conflicts of interest.
  • V Kataja: No conflicts of interest.
  • I Kunkler: No conflicts of interest.
  • A Łacko: Honoraria from AstraZeneca, Novartis, Roche; travel support from Roche.
  • M Leidenius: No conflicts of interest.
  • MG Mastropasqua: No conflicts of interest.
  • O Pagani: No conflicts of interest.
  • S Paluch-Shimon: No conflicts of interest.
  • F Penault-Llorca: No conflicts of interest.
  • M Pestrin: No conflicts of interest.
  • M Pollán: No conflicts of interest.
  • P Poortmans: No conflicts of interest.
  • E Senkus: Honoraria from AstraZeneca, Celgene, Pfizer, Roche; travel support from Amgen, AstraZeneca, Pfizer, Roche.
  • B Sousa: No conflicts of interest.
  • N Turner: No conflicts of interest.
  • G Viale: No conflicts of interest.
  • G von Minckwitz: Research grants from GlaxoSmithKline, Novartis, Roche, Teva, Sanofi-Aventis.
  • C Vrieling: No conflicts of interest.
  • H Wildiers: No conflicts of interest.
Chapter 1 - Diagnosis and Staging of Breast Cancer

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings